Researchers at the University at Buffalo have put the "pop" into drug delivery by releasing compounds from liposomes called nanoballoons that break open upon being hit with a laser.
On a cold January morning in 2013, my big sister, Gretchen, took her last, labored breath and died. She was 46. Over the course of her last month alive, I developed a growing sense of anger and desperation at how her doctors, as well as the drug and diagnostics industries, seemed to have failed her.
Researchers have developed gold nanoparticles that could act as a cancer treatment by heating up and destroying tumor cells when they absorb near-infrared light. And the scientists have made the so-called plasmonic particles in a way that can be reproduced in bulk.
A team of researchers has developed microparticles capable of carrying three different molecules on three different docks, or "patches." They could eventually provide a one-two-three punch against cancer, the researchers say.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a light-activated delivery system for chemotherapy.
Miltenyi Biotec said today that the FDA had approved its device for humanitarian use in patients with acute myeloid leukemia (AML) who are getting allogeneic stem cell transplants from matched, related donors. The device, called the CliniMACS CD34 Reagent System, is designed to lower the risk of graft-versus-host disease (GVHD), which is a common complication of this type of transplant.
Researchers have found that gravity and electrostatics are two important factors at play between cell membranes and drug reservoirs. With these new findings, the scientists hope to create systems that deliver cancer drugs slowly and continuously.
Microlin Bio a fledgling diagnostic and drug developer, filed plans to raise as much as $25 million in a modest initial public offering designed to advance work on tests and related therapies for four different kinds of cancers.
Like any moving target, cancer that has metastasized is notoriously difficult to treat. One of the major hurdles in cancer research is the detection of cancer cells that have spread in the body, but researchers at Cornell have developed a compound that could piggyback on white blood cells and deliver cancer-killing drugs very effectively.
In its new, $15 million round of late-stage financing, metabolomics-focused Metabolon has added Camden Partners and Sumitomo to its list of investors.